Skip to main content
Back
Watch Compare

Silence Therapeutics plc

Data quality: 100%
Also listed as SLNCF NASDAQ
SLN
NASDAQ Manufacturing Chemicals
$7.39
▲ $0.11 (1.51%)
6 months return
—
Momentum
Neutral
ROE
-105.35%

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-98.71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-105.35%
Below sector avg (-54.68%)
ROIC-51.42%
Net Margin-15851.88%
Op. Margin-16292.84%

Safety

Debt / Equity
N/A
Current Ratio7.69
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-3.02 | -10.11
Below sector avg (-1.50)
P/B Ratio3.61
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -62.33 M
Capital efficient — spends only 9.84% of revenue on capex

Price History

Financial Trends

Analyst Price Target

5 analysts
Buy
+343.8%
upside to target
Current
$7.39
Consensus Target
$32.80
$4.00
Low
$75.00
High
Forecast
Forward P/E
-10.11
Forward EPS
-$0.72
Est. Revenue
4.68 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.19 · Rev Est: 1.55 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.60 -$0.55 -$0.15 -$0.27 — —
Estimate -$0.42 -$0.21 -$0.21 -$0.49 -$0.19 -$0.21
Surprise -44.58% -166.66% +27.42% +44.90% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -98.71% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -105.35% · Net Margin: -15851.88%
Revenue (TTM) 559,000.0 Net Income (TTM) -88.61 M
ROE -105.35% ROA -56.80%
Gross Margin 61.54% Operating Margin -16292.84%
Net Margin -15851.88% Free Cash Flow (TTM) -62.33 M
ROIC -51.42% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 7.69
Debt / Equity N/A Current Ratio 7.69
Interest Coverage N/A Asset Turnover 0.00
Working Capital 116.25 M Tangible Book Value 63.45 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -3.02 · EV/EBITDA: N/A
P/E Ratio -3.02 Forward P/E -10.11
P/B Ratio 3.61 P/S Ratio 478.25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 57.09 Fwd Earnings Yield N/A
FCF Yield -23.31%
Market Cap 267.34 M Enterprise Value 185.31 M

Per Share

EPS: -0.63 · FCF/Share: -1.32
EPS (Diluted TTM) -0.63 Revenue / Share 0.01
FCF / Share -1.32 OCF / Share -1.32
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 70.34% · CapEx/Rev: 9.84%
CapEx / Revenue 9.84% FCF Conversion 70.34%
SBC-Adj. FCF -70.40 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 559,000.0 43.26 M
Net Income -88.61 M -45.31 M
EPS (Diluted) -0.63 -0.33
Gross Profit 344,000.0 31.45 M
Operating Income -91.08 M -63.32 M
EBITDA — —
R&D Expenses 67.75 M 67.88 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax 11,000.0 845,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 131.44 M 202.64 M
Total Liabilities 69.14 M 68.61 M
Shareholders' Equity 62.30 M 134.02 M
Total Debt — —
Cash & Equivalents 11.28 M 121.33 M
Current Assets 118.66 M 187.37 M
Current Liabilities 13.61 M 16.82 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -3.0 -1.5
P/B 3.6 1.6
ROE % -105.4 -54.7
Net Margin % -15851.9 -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3

ETFs Holding This Stock
BBC logo BBC Virtus Biotech Clinical Trials ETF
0.89% weight
SNTKX SNTKX
0.01% weight
SNTCX SNTCX
0.01% weight
SNTFX SNTFX
0.01% weight
SNTDX SNTDX
0.01% weight